Immunology / Virology & Vaccines

Scan of the lungs showing tuberculosis
#Immunology / Virology & Vaccines #TB vaccine #Tuberculosis #University of Oxford

Human infection model drives forward TB vaccine development

For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. Researchers from the University of Oxford developed the infection model, which replicates how TB enters the body by infecting people… Read More

#News

HIV cell
#Biotechnology #Clinical trials #HIV #Immunology / Virology & Vaccines #Naobios #Sumagen

Naobios and Sumagen partner to develop HIV vaccine 

Naobios has signed a partnership agreement with Sumagen, a Korean-Canadian biotechnology company developing an HIV-1 vaccine candidate, to manage the manufacturing process during its Phase II clinical trials.  At the end of 2022, the World Health Organization (WHO) reported that approximately 39 million people were living with… Read More

#Business & Investment #News

Vaccine
#GlobalData #Immunology / Virology & Vaccines #TB vaccine #Tuberculosis

World Tuberculosis Day 2024: New vaccines offer hope

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. World TB Day is marked annually on 24 March, the anniversary of the discovery of the causative mycobacterium by… Read More

#News

#Antimicrobial resistance (AMR) #Cell and gene therapy #Europe #Immunology / Virology & Vaccines #Market reporting #mRNA #Plant-based

Read the Spring issue of DDW now

The Spring issue of Drug Discovery World (DDW) is out now. It looks at where we are in the fight against antimicrobial resistance, explores how structural biology is informing vaccine design, and offers advice on approaching dealmaking in biopharma. Read the digital version here. … Read More

#News

EBV virus
#Epstein-Barr virus #Immunology / Virology & Vaccines #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases

Monoclonal antibody could protect against Epstein-Barr virus

Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for the virus. The research was led by Jeffrey Cohen and colleagues from the National Institute of Allergy… Read More

#News

Trophy
#Awards #Immunology / Virology & Vaccines #Scotland #Valneva

Two wins for vaccine company at Scotland’s Life Sciences Awards

Valneva Scotland scooped two prizes at Scotland’s Life Sciences Awards 2024, including the award for Innovation – Pharma Services And Drug Discovery, in a ceremony on 14 March in Glasgow. Valneva Scotland is focused on vaccines for infectious diseases with significant unmet medical needs. Read More

#News

Vaccine vial and syringe
#Covid variants #Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Omicron

Vaccine monitoring crucial as SARS-CoV-2 evolves

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The Francis Crick Institute and the National Institute for Health and Care Research Biomedical Research Centre at University College Hospitals London (UCLH) published their… Read More

#News #Trending News

Antibodies
#Antibodies #Flu #Flu vaccine #Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH)

Novel antibodies target ‘dark side’ of influenza virus protein

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored ‘dark side’ of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many… Read More

#Editor's Choice #News

Doctor prepares vaccine
#Cancer vaccine #Genetic diseases #ImmunityBio #Immunology / Virology & Vaccines #Oncology #Phase II trial

Combination cancer vaccine to be assessed in Phase II trial

The first 20 participants have been enrolled in a multicentre trial to test whether ImmunityBio’s Nant Cancer Vaccine (NCV) could potentially prevent colon and other cancers in individuals with Lynch syndrome. The vaccine comprises a tri-valent Adenovirus (Tri-Ad5) in combination with the company’s IL-15 superagonist N-803. Read More

#Cancer Research #News

Cardiovascular system
#Cardiovascular disease #Immunology / Virology & Vaccines #Preclinical investigations #Vaxxinity

Vaccine successfully lowers cholesterol in preclinical studies

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease. VXX-401 is a synthetic… Read More

#News

#Artificial intelligence (AI) #Drug discovery #Funding #Ginkgo #Immunology / Virology & Vaccines #Machine learning #Vaccine adjuvants

Ginkgo Bioworks to discover and develop novel vaccine adjuvants 

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD)… Read More

#News

Vaccine
#Immunology / Virology & Vaccines #Phase I trial #Rabies #Replicate Bioscience #srRNA

Positive initial results for srRNA rabies vaccine

Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000, participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg). Read More

#News

Vaccine discovery
#Covid-19 #Immunity #Immunology / Virology & Vaccines #Pandemic prevention #Vaccines

Accelerating recombinant protein vaccine discovery

Listen to this article on the DDW Podcast: Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason), Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. Technologies that hasten… Read More

#Exclusive Content

Human antibodies
#Animal models #Antibodies #HIV #Immunology / Virology & Vaccines #NIAID

Antibodies protect against HIV in animal studies

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. The antibodies – a human broadly neutralsing antibody and two antibodies isolated from previously vaccinated monkeys – target… Read More

#News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

New DDW Highlights podcast: 22 January 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With seasonal illnesses running amok in the western hemisphere at the moment, it is… Read More

#News

#Covid-19 #Immune system #Immunity #Immunology / Virology & Vaccines #Influenza #Stem cell transplant #TB vaccine

This week in drug discovery (15-19 January) 

News round-up for 15-19 January by DDW Digital Content Editor Diana Spencer. With seasonal illnesses running amok in the western hemisphere at the moment, it is perhaps not surprising that this week’s news highlights focus on viruses and immunity. The top stories: Antibody… Read More

#News